Shilpa Medicare Ltd (SHILPAMED) is currently trading at 954.65 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Shilpa Medicare is an integrated pharmaceutical company operating API manufacturing, finished formulations and an expanding biologics and CDMO platform that covers small molecules, peptides, ADCs and biosimilars across regulated global markets including the US and Europe. The company delivered a record Q1 FY27 with consolidated revenue of INR469 crore (up 43% YoY) and EBITDA of INR139 crore at a 30% margin, driven by strong Formulation growth, CDMO wins and increased biologics licensing and service income. Shilpa Medicare has materially de-risked its balance sheet and improved returns: net debt-to-EBITDA reduced from 6.7x to 1.3x over recent years, ROCE moved into double digits, and a credit rating upgrade to AA- reflects meaningful financial strengthening alongside operational progress. Strategic pipeline and commercialization readouts are near-term drivers: over 25 NCE programs in APIs, three late-stage NCEs expected to commercialize in FY28, biologics programs (ADC, albumin, Aflibercept, Nivolumab) entering human studies or India launches in FY27–FY28, implying sizeable revenue carry-forward. Management states reinvesting is largely complete and harvesting has begun: selective capex continues (peptide capacity) while the company aims to increase utilization of existing assets and monetize partnerships and licensing to drive margin expansion and improved asset turns.

Over the past 52 weeks, Shilpa Medicare Ltd has traded between a low of ₹260.00 and a high of ₹1,095.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Shilpa Medicare Ltd has a market capitalization of approximately 18,288.86. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Shilpa Medicare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 61.51 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 18,288.86 Cr, Shilpa Medicare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Shilpa Medicare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Shilpa Medicare Ltd is 61.51. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

CDSCO granted final marketing authorization for OERIS, an extended-release ondansetron injection developed by Shilpa Medicare for chemotherapy-induced nausea and vomiting (CINV).

The board met on August 5, 2026 to approve the unaudited standalone and consolidated results for the quarter ended June 30, 2026.

The dataset states the board met on August 5, 2026 to approve the unaudited results for the quarter ended June 30, 2026.

The stock rose after Shilpa disclosed an exclusive Europe commercialisation deal with Orion for Recombinant Human Albumin and reported record quarterly revenue and EBITDA with margins around 30%.